Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03105362 · ClinicalTrials.gov registry record · NA
Amino Acid-based Oral Rehydration Solution in Children With Short Bowel Syndrome
A NA study, sponsored by Boston Children's Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT03105362: Clinical Trial NA study, sponsored by Boston Children's Hospital.
NCT03105362 is a NA study that was terminated before completion, run by Boston Children's Hospital. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03105362, a NA study, was terminated before completion, sponsored by Boston Children's Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will assess the tolerability and palatability of an amino acid based oral rehydration solution (enterade®) compared to current oral rehydration solution among children with short bowel syndrome .
Primary Outcome
Ostomy output measured as milliliters per day. The mean of outputs where compared between week 1(day 1-7) and week 2 (day 8-14). The difference (of the means) between weeks were reported.
Interventions
- DIETARY_SUPPLEMENT Enterade® oral rehydration solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2018-04-03 |
| Phase | NA |
Why NCT03105362 stopped before completion
NCT03105362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Enterade® oral rehydration solution is the first listed.
NCT03105362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03105362 about?
NCT03105362 is a clinical study titled "Amino Acid-based Oral Rehydration Solution in Children With Short Bowel Syndrome". This study will assess the tolerability and palatability of an amino acid based oral rehydration solution (enterade®) compared to current oral rehydration solution among children with short bowel syndrome .
What is the current status of trial NCT03105362?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2017-08-16. Estimated completion is 2018-04-03.
What interventions are being tested in trial NCT03105362?
The interventions under investigation include: Enterade® oral rehydration solution (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03105362?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03105362's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI